HBK Investments L P Has $3.87 Million Position in Eli Lilly and Co (NYSE:LLY)

HBK Investments L P raised its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 133.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 45,800 shares of the company’s stock after purchasing an additional 26,202 shares during the period. HBK Investments L P’s holdings in Eli Lilly and were worth $3,868,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Avestar Capital LLC purchased a new position in Eli Lilly and during the 4th quarter valued at about $100,000. Gradient Investments LLC purchased a new position in shares of Eli Lilly and in the 4th quarter worth approximately $103,000. MPS Loria Financial Planners LLC purchased a new position in shares of Eli Lilly and in the 2nd quarter worth approximately $128,000. San Francisco Sentry Investment Group CA purchased a new position in shares of Eli Lilly and in the 2nd quarter worth approximately $129,000. Finally, Front Row Advisors LLC purchased a new position in shares of Eli Lilly and in the 4th quarter worth approximately $137,000. 77.63% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

NYSE:LLY traded down $1.77 during trading hours on Friday, hitting $76.85. 4,012,829 shares of the company were exchanged, compared to its average volume of 4,066,183. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.85. Eli Lilly and Co has a 52-week low of $73.69 and a 52-week high of $89.09. The company has a market cap of $84,196.70, a PE ratio of 17.96, a P/E/G ratio of 1.40 and a beta of 0.26.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, beating the consensus estimate of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The business had revenue of $6.16 billion during the quarter, compared to analysts’ expectations of $5.93 billion. During the same period in the previous year, the business posted $0.95 EPS. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. analysts expect that Eli Lilly and Co will post 4.87 EPS for the current fiscal year.

In other Eli Lilly and news, insider Donald A. Zakrowski sold 860 shares of Eli Lilly and stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $76.50, for a total transaction of $65,790.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Donald A. Zakrowski sold 876 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $77.55, for a total transaction of $67,933.80. Following the sale, the insider now owns 4,130 shares of the company’s stock, valued at $320,281.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 15,261 shares of company stock valued at $1,225,085. Company insiders own 0.11% of the company’s stock.

A number of research analysts have recently issued reports on LLY shares. Jefferies Group set a $93.00 price objective on shares of Eli Lilly and and gave the stock a “buy” rating in a research report on Monday, February 26th. Goldman Sachs downgraded shares of Eli Lilly and from a “buy” rating to a “neutral” rating and lifted their price objective for the stock from $86.98 to $95.00 in a research report on Tuesday, January 16th. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $85.00 price objective on the stock in a research report on Tuesday, April 3rd. Argus raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $85.52 to $115.00 in a research report on Friday, January 5th. Finally, Bank of America cut their price objective on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a research report on Thursday, February 1st. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company. Eli Lilly and has a consensus rating of “Hold” and a consensus target price of $92.84.

WARNING: This article was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/08/hbk-investments-l-p-boosts-holdings-in-eli-lilly-and-co-lly.html.

Eli Lilly and Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply